Phase II CITYSCAPE: Addition of Tiragolumab, an Anti-TIGIT Antibody, to First-line Atezolizumab in PD-L1–Selected Metastatic NSCLC

May 29-31, 2020; Online at meetings.asco.org/am
Dual immune checkpoint inhibition with tiragolumab plus atezolizumab achieved meaningful improvement in ORR and PFS with comparable safety vs placebo plus atezolizumab, with the greatest benefit among patients with PD-L1 TPS ≥ 50%.
Format: Microsoft PowerPoint (.ppt)
File Size: 286 KB
Released: June 5, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

An expert nurse practitioner provides guidance on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 4, 2022 Expired: October 3, 2023

Download this expert slideset on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Released: October 4, 2022

Expert text module from Dr. Catherine Shu on clinical trial highlights for EGFR-mutated advanced NSCLC, from Clinical Care Options (CCO)

person default Catherine A. Shu, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 30, 2022 Expired: September 29, 2023

Experts review oncology HCP survey results on key educational needs in managing EGFR-mutated NSCLC, including discussion of SoC practices and ongoing challenges, from Clinical Care Options (CCO)

Edward B. Garon, MD, MS
Program Director
Xiuning Le, MD, PhD Zofia Piotrowska, MD, MHS Mark A. Socinski, MD Helena A. Yu, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: September 30, 2022 Expired: September 29, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings